Please assess the completion status of the following clinical trial:

Trial Title: Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 9 years of age.~* Primary, axillary hyperhidrosis of at least 6 months duration.~* Hyperhidrosis Disease Severity Scale (HDSS) of 3 or 4 at Baseline.~* Axillary Sweating Daily Diary (ASDD) ≥ 4 at Baseline.~* Sweat production of at least 50 mg over 5 minutes in each axilla assessed gravimetrically.~Exclusion Criteria:~* Prior surgical procedure for hyperhidrosis.~* Prior axillary treatment with an anti-hyperhidrosis medical device (approved or investigational).~* Prior treatment with botulinum toxin (e.g., Botox®) for axillary hyperhidrosis within 1 year of Baseline/Day 1.~* Previous active treatment in the Dermira DRM04-HH01 or DRM04-HH02 clinical trials.~* Axillary use of nonprescription antiperspirants within 1 week or prescription antiperspirants within 2 weeks of Baseline.~* Subjects on new or regimens of psychotherapeutic medications that have changed within 2 months of baseline.~* Treatment with systemic anticholinergics within 4 weeks of the baseline visit unless dosing has been stable for at least 4 months.~* Other treatment with glycopyrrolate within 4 weeks prior to Baseline.~* Secondary axillary hyperhidrosis or presence of a condition that may cause secondary hyperhidrosis.~* History of Sjögren's syndrome or Sicca syndrome.~* History of glaucoma, inflammatory bowel disease, toxic megacolon, or febrile illness.~* Men with a history of urinary retention requiring catheterization due to prostatic hypertrophy or severe obstructive symptoms of prostatic hypertrophy.~* History or presence of ventricular arrhythmias, atrial fibrillation, atrial flutter.~* Other systemic diseases or active uncontrolled infections, or any other condition which, in the judgment of the Investigator, would put the subject at unacceptable risk for participation in the study.

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- glycopyrronium (Type: EXPERIMENTAL): glycopyrronium Topical Wipes
- Vehicle (Type: PLACEBO_COMPARATOR): glycopyrronium Topical Wipes, Vehicle

Based on this trial design, predict the completion outcome and termination type (if applicable).